GH Research (GHRS) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GH Research (GHRS) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 60.9% versus a loss of 5.8%. Maze Therapeutics is the larger company by market cap ($1.40 billion vs $1.38 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | MAZE |
|---|---|---|
| Share price | $20.13 | $25.27 |
| Market cap | $1.38B | $1.40B |
| 1-day change | -4.43% | -3.73% |
| YTD return | +65.83% | -36.64% |
| 1-year return | +60.89% | -5.78% |
| 5-year return | +23.88% | — |
| EPS (TTM) | $-0.99 | $-2.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.44 | $53.65 |
| 52-week low | $12.04 | $21.95 |
| Distance from 52-week high | -35.99% | -52.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +113.12% | +143.35% |
| Average volume | 296.90K | 560.26K |
| Shares outstanding | 68.64M | 55.55M |
| Employees | 73 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed MAZE by 66.7 percentage points over the past year.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
GHRS vs MAZE FAQ
Which is bigger, GH Research or Maze Therapeutics?
Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.40B compared with $1.38B for GH Research (GHRS).
Which stock has performed better over the past year, GHRS or MAZE?
GHRS returned +60.89% over the past 12 months, compared with -5.78% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Maze Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for GH Research and Biotechnology: Biological Products (No Diagnostic Substances) for Maze Therapeutics.